Two Bispecific Antibodies Join Forces, Cutting Progression Risk by 89% in Phase 3 Multiple Myeloma Trial

Multiple myeloma frequently relapses after treatment, and patients often have fewer options with each subsequent line of therapy. Johnson & Johnson announced that the combination of two off-the-shelf bispecific antibodies, Tecvayli (teclistamab) and Talvey (talquetamab), substantially reduced the risk of disease progression or death in the Phase 3 MonumenTAL-6 trial. The trial also provides the first randomized controlled data supporting a strategy that simultaneously targets two myeloma antigens.

This global, randomized, three-arm trial, registered as NCT06208150, enrolled adults with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy. All participants had previously received lenalidomide and an anti-CD38 antibody. The two experimental groups received either Tecvayli plus Talvey or Talvey plus pomalidomide, while the control group received an investigator-selected standard regimen of EPd or PVd. The primary endpoint was progression-free survival assessed by an independent committee.

The company’s interim analysis showed that Tecvayli plus Talvey reduced the relative risk of disease progression or death by 89% versus the control group, with a hazard ratio of 0.11. The relative risk of death was reduced by 62%, with a hazard ratio of 0.38. Talvey plus pomalidomide also met the primary endpoint, reducing the risk of disease progression or death by 73%, with a hazard ratio of 0.27. The company said both experimental groups achieved statistically significant and clinically meaningful improvements in progression-free survival and overall survival, prompting the independent data monitoring committee to recommend unblinding the trial.

Both drugs recruit T cells through CD3 to attack myeloma cells, but they recognize different tumor markers: Tecvayli targets BCMA, while Talvey targets GPRC5D. The dual-target design is intended to cover different tumor-cell populations simultaneously, reducing the chance that cancer cells can evade immune attack by decreasing or losing a single antigen. Their off-the-shelf antibody format also does not require individualized manufacturing for each patient, unlike autologous cell therapies.

Although the efficacy figures are striking, they do not mean that “89% of patients no longer experienced progression.” A hazard ratio describes the relative difference in the rate of events between two groups during follow-up. The announcement has not yet provided the median progression-free survival for each group, absolute survival rates, duration of response, minimal residual disease negativity rates, or complete patient characteristics. The summary data therefore cannot yet show how long the benefit may last or which patients benefit most.

Safety also requires clarification through complete data. The company stated only that the overall safety profiles of both experimental groups were consistent with existing experience for each drug as monotherapy, without disclosing group-specific figures for serious infections, treatment discontinuations, or treatment-related deaths. Tecvayli and Talvey both carry the highest-level warnings for cytokine release syndrome and neurologic toxicity and must be supplied in the United States through a shared Risk Evaluation and Mitigation Strategy program. Full results are expected to be presented at a future medical meeting and submitted to regulators in multiple countries. Only then will it become clearer whether the risk-benefit profile supports moving the dual-antibody combination earlier in the treatment sequence.